Neon Therapeutics to Present at Morgan Stanley 16th Annual Global Healthcare Conference

CAMBRIDGE, Mass., Sept. 06, 2018 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced that management will participate in a fireside chat at the Morgan Stanley 16th Annual Global Healthcare Conference on Friday, September 14, 2018 at 9:55 a.m. ET.

A live webcast of the presentation will be available by visiting the Investors section of Neon Therapeutics’ website at A replay of the webcast will be archived on the Neon Therapeutics website for 30 days following the presentation.

About Neon Therapeutics

Neon Therapeutics is a clinical-stage immuno-oncology company and a leader in the field of neoantigen-targeted therapies, dedicated to transforming the treatment of cancer by directing the immune system towards neoantigens. Neon is using its neoantigen platform to develop both vaccine and T cell therapies, including NEO-PV-01, a clinical stage neoantigen vaccine for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of a subset of estrogen-receptor-positive breast cancer.

For more information, please visit

Media Contact:
Stephanie Simon, Ten Bridge Communications

Investor Contact:
Will O’Connor, Stern Investor Relations